Full Press Release Details
T2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company Update
Submitted 510(k) Application to the FDA Requesting Market Clearance for T2Bacteria Panel
Year over Year Quarterly Product Revenue Growth of 27.4%
LEXINGTON, Mass., November 2, 2017 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in
the development of innovative diagnostic products to improve patient health, announced today operating highlights and financial results for the third quarter ended September 30, 2017.
Third Quarter Business and Financial Performance Highlights:
Our operating progress in the third quarter was one of the best we have
had, said John McDonough, president and chief executive officer of T2 Biosystems. We completed the T2Bacteria Panel FDA filing for market clearance, closed two exciting new partnerships one with the CDC for the detection of the
Candida auris superbug and the other with Cidara to facilitate clinical trial recruitment, both of which could lead to new revenue opportunities for the company, and closed a $20.1 million gross equity financing. Total company revenue
was in line with our guidance while product revenue was slightly behind, due to orders received late in the quarter that could not be shipped by quarter end.
Third Quarter Financial Results:
Total revenue for the third quarter of $1.1 million increased 2% over the third quarter of 2016 and 15.8% over the second quarter of this year. Product
revenue for the third quarter of 2017 was up 27.4% from the third quarter of 2016 while growing slightly from the second quarter of this year. Product revenue was negatively impacted by an order received late in the quarter that could not be shipped
in the third quarter. Research revenue in the third quarter of 2017 of $369,000 exceeded our guidance of less than $100,000, however declined year over year by $135,000 as expected, primarily due to a decline in revenue recognized from our co-development agreement with Canon U.S. Life Sciences.
Operating expenses, excluding cost of product revenue, in the
third quarter decreased sequentially from the second quarter of 2017 by $1.4 million and increased $304,000 to $11.4 million, from $11.1 million in the third quarter of 2016. The quarterly year-over-year increase in operating expense
was primarily driven by a $680,000 increase in research and development expenses, offset by a $376,000 reduction in SG&A expenses.
attributable to common shareholders for the third quarter of 2017 was $14.1 million, or $0.45 per basic and diluted share, compared to a net loss of $12.8 million or $0.51 per basic and diluted share in the same period of the prior year.
Cash and cash equivalents as of September 30, 2017 was $52.9 million and reflects the equity financing completed in September which raised an
additional $18.8 million in net proceeds which, together with the additional remaining liquidity on the Company s term loan of up to $10 million, should extend the company s cash runway into the first half of 2019.
Outlook for Remainder of 2017:
The company is updating
guidance for 2017, as follows:
Management will host a conference call
today with the investment community at 4:30 p.m. Eastern Time to discuss the financial results and other business developments. Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784
(International). To listen to the live call via T2 Biosystems website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call,
also in the Investors/Events & Presentations section of the website.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering
clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis
Solution is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems products, including the T2Dx Instrument and T2Candida Panel, and the T2Bacteria Panel, which is commercially available in
Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR , the T2Sepsis Solution
is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of
dollars in savings. T2 Biosystems has an active pipeline of future sepsis products, including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding additional patients, timing of testing patients, anticipated product benefits, strategic priorities, product expansion or opportunities, growth expectations or targets, timing of FDA
filings or clearances and anticipated operating expenses, as well as statements that include the words expect, intend, plan , believe , project , forecast , estimate,
may, should, anticipate, and similar statements of a future or forward looking nature. These forward-looking statements are based on management s current expectations. These statements are neither promises
nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring
products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or
(i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at
all; or (iv) the factors discussed under Item 1A. Risk Factors in the company s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 15, 2017, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking statements represent management s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no
one should assume that the Company s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements
should not be relied upon as representing the company s views as of any date subsequent to the date of this press release.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 739 | $ | 580 | $ | 2,105 | $ | 1,168 | ||||||||
| Research revenue | 369 | 504 | 900 | 2,003 | ||||||||||||
| Total revenue | 1,108 | 1,084 | 3,005 | 3,171 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of product revenue | 2,106 | 1,894 | 5,722 | 4,701 | ||||||||||||
| Research and development | 5,880 | 5,200 | 19,577 | 18,160 | ||||||||||||
| Selling, general and administrative | 5,559 | 5,935 | 17,192 | 18,282 | ||||||||||||
| Total costs and expenses | 13,545 | 13,029 | 42,491 | 41,143 | ||||||||||||
| Loss from operations | (12,437 | ) | (11,945 | ) | (39,486 | ) | (37,972 | ) | ||||||||
| Interest expense, net | (1,718 | ) | (876 | ) | (5,008 | ) | (2,416 | ) | ||||||||
| Other income, net | 79 | 38 | 260 | 133 | ||||||||||||
| Net loss and comprehensive loss | $ | (14,076 | ) | $ | (12,783 | ) | $ | (44,234 | ) | $ | (40,255 | ) | ||||
| Net loss per share basic and diluted | $ | (0.45 | ) | $ | (0.51 | ) | $ | (1.43 | ) | $ | (1.64 | ) | ||||
| Weighted-average number of common shares used in computing net loss per share basic and diluted | 31,420,726 | 25,027,751 | 30,873,930 | 24,524,508 |
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| September 30, 2017 | December 31, 2016 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 52,897 | $ | 73,488 | ||||
| Accounts receivable | 442 | 327 | ||||||
| Prepaid expenses and other current assets | 754 | 820 | ||||||
| Inventories, net | 1,254 | 803 | ||||||
| Total current assets | 55,347 | 75,438 | ||||||
| Property and equipment, net | 13,854 | 13,589 | ||||||
| Restricted cash | 260 | 260 | ||||||
| Other assets | 218 | 281 | ||||||
| Total assets | $ | 69,679 | $ | 89,568 | ||||
| Liabilities and stockholders equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 993 | $ | 962 | ||||
| Accrued expenses and other current liabilities | 5,513 | 4,908 | ||||||
| Current portion of notes payable | 1,416 | 1,269 | ||||||
| Deferred revenue | 2,076 | 2,445 | ||||||
| Current portion of lease incentives | 247 | 301 | ||||||
| Total current liabilities | 10,245 | 9,885 | ||||||
| Notes payable, net of current portion | 40,089 | 39,504 | ||||||
| Lease incentives, net of current portion | 751 | 792 | ||||||
| Other liabilities | 467 | 49 | ||||||
| Stockholders equity: | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016 | ||||||||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 35,796,322 and 30,482,712 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 36 | 30 | ||||||
| Additional paid-in capital | 266,014 | 242,997 | ||||||
| Accumulated deficit | (247,923 | ) | (203,689 | ) | ||||
| Total stockholders equity | 18,127 | 39,338 | ||||||
| Total liabilities and stockholders equity | $ | 69,679 | $ | 89,568 |
Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
Amy Phillips, Feinstein Kean Healthcare
Chris Brinzey, Westwicke Partners